Baker BROS. Advisors LP Purchases 731,588 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Baker BROS. Advisors LP boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 77.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,670,762 shares of the biotechnology company’s stock after purchasing an additional 731,588 shares during the quarter. Arrowhead Pharmaceuticals comprises about 0.4% of Baker BROS. Advisors LP’s portfolio, making the stock its 25th biggest position. Baker BROS. Advisors LP owned 1.21% of Arrowhead Pharmaceuticals worth $57,625,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Marex Group plc bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $576,000. Nordea Investment Management AB grew its holdings in Arrowhead Pharmaceuticals by 74.5% during the 3rd quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock worth $12,661,000 after acquiring an additional 158,937 shares in the last quarter. Marshall Wace LLP increased its position in Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the period. HBK Sorce Advisory LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $2,823,000. Finally, Erste Asset Management GmbH lifted its position in shares of Arrowhead Pharmaceuticals by 55.3% in the 3rd quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock worth $2,466,000 after purchasing an additional 26,000 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $55.05 on Friday. The business’s fifty day simple moving average is $64.47 and its 200-day simple moving average is $51.36. The company has a market cap of $7.71 billion, a PE ratio of 35.98 and a beta of 1.23. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. During the same quarter in the prior year, the company posted ($1.39) EPS. The business’s revenue for the quarter was up 10461.3% on a year-over-year basis. Analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the sale, the chief operating officer owned 474,908 shares in the company, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $67.66, for a total value of $676,600.00. Following the sale, the director owned 33,600 shares in the company, valued at $2,273,376. The trade was a 22.94% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 495,836 shares of company stock valued at $32,759,810. 3.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on ARWR. Royal Bank Of Canada lifted their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. B. Riley Financial upped their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Weiss Ratings upgraded Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. Morgan Stanley lifted their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 7th. Finally, The Goldman Sachs Group boosted their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $81.67.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.